10-QPeriod: Q3 FY2017

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 2017

Filed October 26, 2017For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) reported its third-quarter 2017 financial results, showing continued revenue growth driven by key products, particularly Opdivo and Eliquis. The company demonstrated solid execution in a competitive pharmaceutical landscape, with a focus on its innovative oncology and cardiovascular portfolios. Despite some challenges, such as patent expirations impacting older products, BMY maintained a strong financial position and continued to invest in its research and development pipeline, signaling a commitment to future growth and product innovation. Investors should note the company's strategic advancements in its key therapeutic areas, which are crucial for long-term value creation. The report highlights the ongoing importance of its biologics, particularly in oncology, as a primary growth driver. Management's discussion of financial condition and results of operations indicates a disciplined approach to capital allocation and a focus on operational efficiency. Overall, BMY appears to be navigating the evolving pharmaceutical market effectively, with its pipeline and key growth products forming the core of its investment thesis.

Financial Highlights

58 data points
Beta

Revenue

$5.25B

69.9% Gross Margin

Net Income

$845.00M

16.1% Net Margin

EPS (Diluted)

$0.51

Total Assets

$33.98B

Cash & Equivalents

$4.64B

Free Cash Flow

$1.45B

Financial Statements
Beta
Revenue$5.25B
Cost of Revenue$1.58B
Gross Profit$3.67B
R&D Expenses$1.56B
SG&A Expenses$1.16B
Operating Expenses$4.07B
Interest Expense$48.00M
Net Income$845.00M
EPS (Basic)$0.52
EPS (Diluted)$0.51
Shares Outstanding (Basic)1.64B
Shares Outstanding (Diluted)1.65B

Key Highlights

  • 1Continued revenue growth driven by flagship products, Opdivo (oncology) and Eliquis (cardiovascular).
  • 2Strong performance in the oncology and cardiovascular segments, underscoring their strategic importance.
  • 3Investment in research and development remains a priority, indicating a commitment to pipeline advancement and future innovation.
  • 4Management maintained a disciplined approach to financial management and operational efficiency.
  • 5The company is navigating patent expirations and competitive pressures while focusing on key growth drivers.
  • 6Solid liquidity and financial position to support ongoing operations and strategic initiatives.

Frequently Asked Questions

Revenue growth was primarily driven by strong performance in key products, notably Opdivo for oncology indications and Eliquis for cardiovascular disease. These innovative biologics continue to be significant contributors to the company's top line.

BMY is strategically focused on its oncology and cardiovascular portfolios, with significant investment and emphasis on developing and commercializing innovative treatments in these areas. The company also has interests in immunology and infectious diseases.

BMY is actively managing the impact of patent expirations on its older products by focusing on the growth of its newer, innovative products like Opdivo and Eliquis. The company is also investing in its R&D pipeline to ensure a continuous stream of new treatments to offset potential revenue declines from mature products and to maintain a competitive edge.

The company continues to prioritize and invest in its research and development pipeline, which is crucial for long-term growth. The Q3 filing indicates a commitment to advancing promising drug candidates in its core therapeutic areas, suggesting a strategic focus on innovation and future product launches.